PDCD1 and neoplasm: If chronic infections or inflammation reduce the efficacy of PD-1 and PD-L1 blockade, it would be through mechanisms other than the induction of the PD-1 and PD-L1 expression in the tumor tissues, as previous studies observed better responses to PD-1 blockade in patients with higher expression of PD-L1 in tumor tissues (51).